Participants should read the activity information, review the activity in its entirety, and complete the online post-test and evaluation. Upon completing this activity as designed and achieving a passing score on the post-test, you will be directed to a Web page that will allow you to receive your certificate of credit via e-mail or you may print it out at that time. The online post-test and evaluation can be accessed at: https://tinyurl.com/NASH19.
Inquiries about the content of this activity may be directed to Global Academy for Medical Education at [email protected] or (973) 290-8225. For information about the accreditation of this program, please contact Global Education Group at (303) 395-1782 or [email protected].
Nikolaos T. Pyrsopoulos, MD, PhD, MBA, FACP, AGAF, FAASLD, FRCP (Edin)
Physician Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group and Global Academy for Medical Education. Global Education Group is accredited by the ACCME to provide continuing medical education for physicians.
Physician Credit Designation
Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education
Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
The increasing global prevalence of nonalcoholic fatty liver disease (NAFLD) and NASH parallels the rise in the incidence of metabolic syndrome and its components, especially obesity (including overweight). NAFLD/NASH has become the second leading cause of liver transplantation in the United States and may soon become the leading cause. Clinicians should be aware of the latest scientific findings about the risk factors for, and pathophysiology of, NAFLD/NASH. Understanding the mechanisms of disease is the basis for designing and deploying an appropriate therapeutic strategy—including lifestyle and use of medications—to slow its progression and improve patient outcomes. Clinicians should also be familiar with new agents now in clinical trials that may provide more options for managing NAFLD/NASH in the near future.
At the conclusion of this program, participants should be better able to:
- Describe at least 2 factors contributing to the increasing prevalence of NAFLD/NASH
- Explain the process for screening for NAFLD/NASH in patients with metabolic risk factors
- Identify a practical stepwise approach to the evaluation of patients with suspected NAFLD/NASH that includes referral to hepatologists
- Describe a comprehensive management strategy for NAFLD/NASH that incorporates lifestyle strategies and approved therapeutic agents
- Discuss the mechanisms of action and trial data on emerging therapeutic agents for the management of NAFLD/NASH
Disclosure of Conflicts of Interest
Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Nikolaos T. Pyrsopoulos, MD, PhD, MBA, FACP, AGAF, FAASLD, FRCP (Edin): Grant/Research Support from Allergan, Bayer, BeiGene, Bristol-Myers Squibb, Conatus, Confirm, Exelixis, GENFIT, Gilead, Hologic, Intercept, Mallinckrodt, Novartis, Prometheus, Resusix, Saro, Shire, and Valeant. Consultant for Bayer, Exelixis, and Gilead.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Global Academy for Medical Education Staff: Shirley V. Jones, MBA; Mike LoPresti; Ron Schaumburg; and Nicola A. Sirdevan, MPA, have nothing to disclose.
Global Education Group: The following planners and managers, Ashley Marostica, RN, MSN; Andrea Funk; Liddy Knight; and Ashley Cann have nothing to disclose.
Fee Information and Refund/Cancellation Policy
There is no fee for this educational activity.
This continuing education supplement was developed from NASH: Expert Insights Into Causes, Diagnosis, and Emerging Treatment Strategies, a live symposium, held during the 6th Annual Digestive Diseases: New Advances Conference on March 16, 2019, at The Westin Philadelphia. The faculty acknowledge the editorial assistance of Global Academy for Medical Education, LLC, and medical writer Ron Schaumburg in the development of this supplement.
The ideas and opinions expressed are those of the faculty and do not necessarily reflect the views of the supporters, Global Academy for Medical Education or Global Education Group.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Global Education Group (Global) and Global Academy for Medical Education do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Copyright © 2019 by Global Academy for Medical Education, LLC, Frontline Medical Communications Inc., and its Licensors. All rights reserved. No part of this publication may be reproduced or transmitted
in any form, by any means, without prior written permission of the Publisher. Global Academy for Medical Education, LLC, the accredited provider, or the Publisher will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.